Obstructive Sleep Apnea SURMOUNT-OSA trials investigated GLP2 in adults with moderate-to-severe obstructive sleep apnea and obesity: Significant improvements in apnea-hypopnea index (AHI) from baseline Benefits observed in participants both using and not using positive airway pressure therapy Improvements correlated with weight reduction FDA approval granted in December 2024 for moderate-to-severe OSA treatment Diabetes Prevention Extended follow-up from SURMOUNT-1 assessed diabetes prevention in participants with prediabetes: 94% reduction in progression to type 2 diabetes compared to placebo over 3 years Nearly all participants with prediabetes at baseline converted to normoglycemia Effects diminished during off-treatment follow-up period, indicating ongoing treatment benefit [CALLOUT BOX Highlighted] Important Context: While GLP2 has demonstrated substantial efficacy in multiple large-scale clinical trials, the majority of data comes from industry-sponsored studies with relatively short follow-up periods (40-72 weeks for most trials)
If the decision is made to re-administer the product, monitor patients for a reoccurrence of signs and symptoms of a severe hypersensitivity reaction
Weight loss is not usually sustained over time after you stop taking them
These responses are written to provide clarity, set realistic expectations, and support informed decision-making before a medical consultation
Jamka M, Woniewicz M, Jeszka J, Mardas M, Bogdaski P, Stelmach-Mardas M
Theyre listening to women they like
